兰列胺降低了血管塑性术后的血清自由和总胰岛素样生长因子I
J Frystyk1, C Skjaerbaek, N Alexander
1Institute of Experimental Clinical Research, Aarhus (Denmark) University Hospital, Denmark.
Circulation
|November 15, 1996
概括
兰胺治疗显著降低胰岛素样生长因子-I (IGF-I) 和增加IGFBP-1 经皮肤透光冠状动脉血管塑造术 (PTCA). 在IGF系统中的这些变化可能会改善长期结果.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素样生长因子-I (IGF-I) 涉及皮肤透光冠状动脉血管塑造术 (PTCA) 后的血管缩.
- 了解治疗干预对IGF系统的影响对于管理PTCA后并发症至关重要.
研究的目的:
- 为了研究lanreotide的效果,一个somatostatin类似物,在循环IGF-I水平和相关因素在接受PTCA的患者.
- 为了确定lanreotide诱导的IGF系统的变化是否与PTCA后改善的长期结果相关.
主要方法:
- 一个受控的临床试验,涉及553名接受PTCA的患者.
- 持续的皮下兰利胺输液与安慰剂的管理.
- 测量血清总和自由IGF-I,IGF-II,IGFBP-1,IGFBP-3以及胰岛素水平.
主要成果:
- 在PTCA后,兰胺显著降低了总IGF-I7%,自由IGF-I降低了22-27%.
- 服用安慰剂的患者表现出自由IGF-I的微不足道增加.
- 兰胺治疗增加了IGFBP-1水平,略有降低了IGF-II和IGFBP-3,而胰岛素水平保持不变.
结论:
- 兰胺急剧减少循环总和自由IGF-I,对自由IGF-I的影响更为明显.
- 兰胺的使用会增加PTCA后的IGFBP-1水平.
- 观察到的IGF系统中由lanreotide引起的变化可能有助于改善PTCA后的长期结果.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...